Logo image of PPCB

PROPANC BIOPHARMA INC (PPCB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PPCB - US74346N7012 - Common Stock

0.66 USD
-0.01 (-1.35%)
Last: 12/24/2025, 7:55:42 PM
0.6428 USD
-0.02 (-2.61%)
After Hours: 12/24/2025, 7:55:42 PM
Fundamental Rating

0

Taking everything into account, PPCB scores 0 out of 10 in our fundamental rating. PPCB was compared to 530 industry peers in the Biotechnology industry. PPCB may be in some trouble as it scores bad on both profitability and health. PPCB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PPCB had negative earnings in the past year.
PPCB had a negative operating cash flow in the past year.
PPCB had negative earnings in each of the past 5 years.
In the past 5 years PPCB always reported negative operating cash flow.
PPCB Yearly Net Income VS EBIT VS OCF VS FCFPPCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

The Return On Assets of PPCB (-2147.26%) is worse than 98.30% of its industry peers.
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROIC N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PPCB Yearly ROA, ROE, ROICPPCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PPCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPCB Yearly Profit, Operating, Gross MarginsPPCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for PPCB has been increased compared to 1 year ago.
Compared to 1 year ago, PPCB has a worse debt to assets ratio.
PPCB Yearly Shares OutstandingPPCB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
PPCB Yearly Total Debt VS Total AssetsPPCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M

2.2 Solvency

Based on the Altman-Z score of -1315.30, we must say that PPCB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PPCB (-1315.30) is worse than 97.74% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1315.3
ROIC/WACCN/A
WACCN/A
PPCB Yearly LT Debt VS Equity VS FCFPPCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -1M -2M -3M

2.3 Liquidity

PPCB has a Current Ratio of 0.00. This is a bad value and indicates that PPCB is not financially healthy enough and could expect problems in meeting its short term obligations.
PPCB has a worse Current ratio (0.00) than 98.30% of its industry peers.
PPCB has a Quick Ratio of 0.00. This is a bad value and indicates that PPCB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of PPCB (0.00) is worse than 98.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0
Quick Ratio 0
PPCB Yearly Current Assets VS Current LiabilitesPPCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

PPCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.43%, which is quite impressive.
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PPCB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPCB Price Earnings VS Forward Price EarningsPPCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPCB Per share dataPPCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -200 -400 -600

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PPCB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROPANC BIOPHARMA INC

NASDAQ:PPCB (12/24/2025, 7:55:42 PM)

After market: 0.6428 -0.02 (-2.61%)

0.66

-0.01 (-1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.84%
Inst Owner ChangeN/A
Ins Owners63.29%
Ins Owner Change0%
Market Cap8.82M
Revenue(TTM)N/A
Net Income(TTM)-1.69M
AnalystsN/A
Price TargetN/A
Short Float %3.36%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-703.62
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.31
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0
Quick Ratio 0
Altman-Z -1315.3
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.4%
OCF growth 3YN/A
OCF growth 5YN/A

PROPANC BIOPHARMA INC / PPCB FAQ

Can you provide the ChartMill fundamental rating for PROPANC BIOPHARMA INC?

ChartMill assigns a fundamental rating of 0 / 10 to PPCB.


Can you provide the valuation status for PROPANC BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to PROPANC BIOPHARMA INC (PPCB). This can be considered as Overvalued.


How profitable is PROPANC BIOPHARMA INC (PPCB) stock?

PROPANC BIOPHARMA INC (PPCB) has a profitability rating of 0 / 10.